
Caribou Biosciences (CRBU) Stock Forecast & Price Target
Caribou Biosciences (CRBU) Analyst Ratings
Bulls say
Caribou Biosciences is attractive fundamentally because its chRDNA gene-editing platform is differentiated, designed to improve specificity and reduce off-target effects, while also avoiding some of the IP complexities that cloud other CRISPR approaches. The company’s focus on validated oncology targets like CD19 and BCMA, combined with its allogeneic CAR-T programs already in the clinic, gives the story a relatively high probability of success and a near-term catalyst with data expected in 2H25. Financially, the stock trading close to cash and the $25 million Pfizer equity investment strengthen the downside case while highlighting external validation of the platform and its potential to improve T-cell persistence and durability.
Bears say
Caribou Biosciences is viewed negatively because it is effectively winding down its core business, with management planning to discontinue further development of both allogeneic CAR-T programs, vispa-cel and CB-011, after citing a challenging financing environment and lack of capital availability. The company’s decision to explore strategic alternatives, including a merger or acquisition, signals that internal execution alone is no longer sufficient, while workforce and cost reductions expected to be completed by 4Q26 underscore the severity of the reset. Although it reported $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, the downside case assumes 0% probability of success across NHL, MM, AML, and the platform, leaving very limited fundamental support.
This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Caribou Biosciences (CRBU) Forecast
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares